MLYS - Rasio utang marang kapitalisasi buku Mineralys

This chart of the current market value of Mineralys Therapeutics (MLYS) reflects the asset's dynamics, with a value of 0.17. Mineralys Therapeutics is developing Lorundrostat to treat severe hypertension by targeting specific enzymes. The operating model relies on external contractors for synthesis and testing, thereby eliminating capital expenditures. The current development stage, characterized by a lack of sales, temporarily limits economies of scale and increases expenses.

This indicator determines the degree of financial leverage by comparing total liabilities to the book value of equity to assess the stability of the financing structure. By analyzing this debt-to-equity chart, an investor can see the reliance of Mineralys Therapeutics (MLYS) on borrowed funds in an environment of zero revenue and total dependence on external investments for drug development.